Skip to content
National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Division of Cancer Prevention logo
Home Site Map Contact DCP
Programs & Resources

Rapid Access to Preventive Intervention Development (RAPID) Program

Supported Investigators

Projects Initiated in:

FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 | FY 2002 | FY 2001
FY 2000

Projects Initiated in FY 2009

Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Chinthalapally V. Rao, PhD
Oklahoma University
Development of phospho-ibuprofen for pancreatic cancer prevention Phospho-ibuprofen

Program Description
Phospho-ibuprofen is covalently modified form of ibuprofen aimed to decrease adverse effects and increase potency of ibuprofen. Preliminary data demonstrated pancreatic chemopreventive effects of phosphor-ibuprofen in vitro and in vivo. The initial RAPID support may include:

  • Scale-up manufacture for preclinical studies and
  • Preclinical toxicological and pharmacological testing

Contact Information
Chinthalapally V. Rao, PhD
Professor of Medicine
Oklahoma University Cancer Institute
Biomedical Research Building, Room 1203,
OU Health Sciences Center
Oklahoma City, OK 73
Phone: (405) 271-3224
Fax: (405) 271-3225


Back to top

Projects Initiated in FY 2008

No awards were made in FY 2008


Projects Initiated in FY 2007

Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Lenard M. Lichtenberger, PhD
The University of Texas
Development of Purified Ibuprofen-PC for Colon Cancer Prevention Ibuprofen-phosphatidylcholine complex

Program Description
Ibuprofen-PC, a non-covalently associated ibuprofen-phosphatidylcholine (PC) complex, may obviate gastro-intestinal toxicities (bleeding and ulceration) of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) as well as cardiovascular toxicity of selective COX-2 NSAIDs. Preliminary studies have shown ibuprofen-PC to have greater efficacy than ibuprofen or aspirin in cell culture and animal colon cancer models. The initial RAPID support may include:

  • Scale-up production method for highly purified ibuprofen-PC

Contact Information
Lenard M. Lichtenberger, PhD
Professor of Integrative Biology and Pharmacology
The University of Texas Health Science Center at Houston
Mailing address: Dept. of Integrative Biology and Pharmacology
The University of Texas Medical School
6431 Fannin
Houston, TX 77030-1503
Phone: (713) 500-6320
Fax: (713) 500-7444


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Hirak S. Basu, PhD
University of Wisconsin
A Novel Prostate Directed Anti-Oxidant (Polyamine Oxidase Inhibitor) for Prostate Cancer Prevention Polyamine oxidase inhibitor, MDL72,527

Program Description
Polyamine oxidase inhibitor MDL72,527 was shown to completely abrogate androgen induced oxidative stress in androgen dependent human prostate cancer cells and markedly reduce oxidative stress in the prostate gland and significantly delay prostate tumor development and prolong the overall survival of the TRansgenic Adenocarcinoma in Mouse Prostate (TRAMP) mice. The initial RAPID support may include:

  • Scale-up manufacture for preclinical studies and
  • Preclinical toxicological and pharmacological testing

Contact Information
Hirak S. Basu, PhD
University of Wisconsin
Paul P. Carbone Comprehensive Cancer Center
K6/522 CSC, 600 Highland Avenue
Madison WI 53792-5669
Phone: (608) 265-4912
Fax: (608) 265-8133


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Doris M. Benbrook, PhD
University of Oklahoma HSC
Flex-Het Chemoprevention Flexible heteroarotinoid, SHetA2

Program Description
Synthetic Flexible Heteroarotinoid (Flex-Het) compounds, even though originally modeled after retinoids, function independently of the retinoid receptors and toxicities. SHetA2 along with other Flex-Hets were shown to induce differentiation and inhibit tumor growth and angiogenesis without evidence of toxicity. The initial RAPID support may include:

  • Scale-up manufacture for preclinical studies and
  • Preclinical toxicological and pharmacological testing

Contact Information
Doris M. Benbrook, PhD
University of Oklahoma HSC
Department of OB/GYN
PO BOX 26901, Room WP 2470
Oklahoma City OK, 73190
Phone: (405) 271-5523
Fax: (405) 271-2976


Back to top

Projects Initiated in FY 2006

Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Glenn Liu, MD
University of Wisconsin
Pentamethylchromanol as a Novel Chemopreventive Antiandrogen and Antioxidant to Prevent Prostate Cancer Progression Pentamethylchromanol

Program Description
2, 2, 5, 7 ,8-pentamethyl-6-chromanol (PMCol) combines two mechanisms of action, anti-androgenic and antioxidant, which have a potential utility for prevention of prostate cancer as shown in preliminary preclinical studies. The initial RAPID support may include:

  • cGMP manufacture for preclinical studies and
  • Preclinical toxicological and pharmacological testing.

Contact Information
Glenn Liu, MD
University of Wisconsin
Madison, WI
Phone: (608) 265-8689
Fax: (608) 265-8133


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Richard Roden, PhD
Johns Hopkins University
Production of a Minor Capsid Protein L2 11-200 Vaccine with Adjuvant for the Prevention of HPV-Associated Disease Capsid Protein L2 11-200 HPV Vaccine

Program Description
Unlike vaccination with L1 VP, vaccination with HPV L2 induces antibodies that cross-neutralize diverse HPV genotypes, suggesting the possibility of a pan-HPV prophylactic vaccine derived from L2 sequences. The project details are under development.

Contact Information
Richard Roden, PhD
Johns Hopkins University
Baltimore, MD
Phone: (410) 502-5161
Fax: (443) 287-4295


Back to top

Projects Initiated in FY 2005

Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Ming You, MD, PhD
Washington University School of Medicine
Anti-tumor B (ATB), Chinese herbal mixture of six plants, for prevention of lung and upper aerodigestive tract tumors Anti-tumor B

Program Description
ATB has exhibited chemopreventive activity in animal models of lung cancer and in previous clinical studies in smokers with bronchial or esophageal dysplasia. The initial RAPID support may include:

  • Development of standardized ATB mixture for use in preclinical and clinical studies
  • Preclinical toxicological and pharmacological testing
  • Isolation, identification, and characterization of key components.

Contact Information
Ming You, MD, PhD
Washington University School of Medicine
St. Louis, MO
Phone: (314) 362-9294
Fax: (314) 362-9366


Back to top

Projects Initiated in FY 2004

Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Michael B. Sporn, MD
Dartmouth Medical School
Bulk synthesis of a new triterpenoid, ethyl 2-carboxy-3,12-dioxooleana-1,9(11)-dien-28-oate (NSC #D722320, TP-222) (concluded) Synthetic Triterpenoid

Program Description
Several new synthetic triterpenoids have shown chemopreventive and chemotherapeutic activities including growth inhibition of leukemia and carcinoma cells, induction of tumor cell differentiation, and suppression of de novo synthesis of COX-2 and iNOS. TP-222 has been synthesized to overcome pharmacokinetic limitations of previous triterpenoids and has shown a promising in vivo activity. The RAPID support will include bulk synthesis of 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) for further evaluation of chemopreventive activity.

Contact Information
Michael B. Sporn, MD
Dartmouth Medical School
Dartmouth, NH
Phone: (603) 650-6557
Fax: (603) 650-1129

Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Russell F. Jacoby, MD
University of Wisconsin-Madison
Polyamine analog SL11217 for prevention of colon and duodenal neoplasia Porphyrin Polyamine Conjugate

Program Description
Experimental evidence suggests that regulating polyamine metabolism may be useful in the prevention and treatment of colon cancer. Polyamine analogs and polyamine synthesis inhibitors have shown chemopreventive activities. SL-11217, a novel porphyrin polyamine conjugate, yielded encouraging preliminary results. It combines the antiproliferative effects of polyamine analogs with tumor-targeting potential of porphyrins which are expected to maximize efficacy and minimize systemic toxicity. The initial RAPID support may include:

  • Scale up GMP synthesis and
  • Preclinical pharmacology and toxicology studies.

Contact Information
Russell F. Jacoby, MD
University of Wisconsin-Madison
Madison, WI
Phone: (608) 256-1901
Fax: (608) 280-7292


Back to top

Projects Initiated in FY 2003

Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Michael B. Sporn, MD
Dartmouth Medical School
Bulk Synthesis of the New Triterpenoid, 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) for Making New Derivatives with Improved Pharmacokinetics (concluded) Synthetic Triterpenoids

Program Description
Investigators will conduct preclinical development of several synthetic triterpenoid derivatives of CDDO. Several new synthetic triterpenoid derivatives of CDDO have exhibited activity in various chemopreventive and chemotherapeutic cell culture models. However, these promising pharmacodynamic properties are limited in vivo by suboptimal pharmacokinetic characteristics of these compounds. CDDO will be used as a starting material for new derivatives with improved pharmacokinetic profiles. RAPID support will include bulk synthesis of 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO).

Contact Information
Michael B. Sporn, MD
Dartmouth Medical School
Dartmouth, NH
Phone: (603) 650-6557
Fax: (603) 650-1129


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Kimberly Kline, PhD and Bob G. Sanders, PhD
University of Texas at Austin
Development of a-TEA, a Novel Tocopherol Based Anticancer Agent, for Prevention of Breast Cancer Recurrence and Metastasis (concluded) Synthetic Vitamin E Derivative

Program Description
Investigators will conduct preclinical development of a-TEA (2,5,7,8-tetramethyl-2R-(4R', 8R', 12'-trimethyltridecyl)chroman-6-yloxy) acetic acid a novel synthetic derivative of naturally occurring vitamin E (RRR-a-tocopherol). Preliminary studies in mouse mammary cancer models showed that this compound can inhibit tumor growth and metastasis without toxicity. It was proposed that it may be effective in preventing breast cancer recurrence and spread. The initial RAPID support will include:

  • Scale up non-GMP synthesis of a-TEA,
  • In vivo preclinical efficacy studies, and
  • Preclinical genotoxicity studies.

Contact Information
Kimberly Kline, PhD and Bob G. Sanders, PhD
University of Texas at Austin
Austin, TX
Phone: (512) 471-8911 (KK)
Phone: (512) 471-7441 (BGS)
Fax: (512) 232-7040 (KK)
(512) 232-7040 (BGS)


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Paul Talalay, MD
Johns Hopkins University School of Medicine
Development of the Glucosinolate of Sulforaphane (Glucoraphanin) to Prevent Familial Adenomatous Polyposis, a Precursor of Colon Cancer, and to Eradicate Helicobacter pylori Infections, a Risk Factor for Gastric Cancer Sulforaphane Precursor (Glucoraphanin)

Program Description
Investigators will conduct preclinical development of the Glucosinolate of Sulforaphane (Glucoraphanin). Glucosinolates (e.g. glucoraphanin) are stable precursors of isothiocyanates and are naturally occurring substances found in cruciferous vegetables. Glucoraphanin and sulforaphane have been isolated from broccoli and its seeds and sprouts and demonstrated to possess significant anticarcinogenic activity, probably mediated by the induction of Phase 2 drug metabolism enzymes. In addition, they also exhibit strong bactericidal activity against intracellular, extracellular and antibiotic resistant H. pylori. RAPID support will include:

  • Process development and scale-up production of high purity glucoraphanin,
  • In vivo preclinical efficacy studies, and
  • Preclinical toxicology studies.

Contact Information
Paul Talalay, MD
Johns Hopkins University School of Medicine
Baltimore, MD
Phone: (410) 955-3499
Fax: (410) 502-6818


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Ling Jong, PhD
SRI International
SR13668: A Novel Dietary Indole Analog for Cancer Prevention (concluded) Synthetic Indole-3-carbinol Derivative

Program Description
Investigators will conduct preclinical development of SR13668, a new synthetic analog of naturally occurring indole-3-carbinol (I3C). I3C is found in cruciferous vegetables (broccoli, cabbage etc.) and exhibits several chemopreventive activities. SR13668 is a result of lead-based rational drug design using computational modeling to optimize chemopreventive I3C activities and minimize its undesirable characteristics. RAPID support will include:

  • Scale up non-GMP synthesis of SR13668 for preclinical studies,
  • In vivo preclinical efficacy studies,
  • Preclinical toxicology studies, and
  • Preclinical pharmacokinetic studies.

Contact Information
Ling Jong, PhD
SRI International
Phone: (650) 859-6121
Fax: (650) 859-3153


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Denis E. Corpet, PhD
Universite De Toulouse, France
Chemoprevention of Colorectal Tumors by Dietary Polyethylene Glycol (PEG) Dietary Polyethylene Glycol (PEG)

Program Description
Investigators will conduct preclinical development of Dietary Polyethylene Glycol (PEG). Water-soluble, high molecular weight polymeric polyethylene glycols are used as food additives and gentle laxatives. They are not absorbed from the gastro-intestinal tract and nor are they metabolized by gut microflora. They possess low toxicity and have recently showed chemopreventive activity in carcinogen-induced colon cancer in rats. Supporting scientific documentation will be presented for consideration of a phase 1/2 clinical study with modulation of aberrant crypt foci as the primary endpoint.

Contact Information
Denis E. Corpet, PhD
Universite De Toulouse, France
Phone: 33-561-1939-82
Fax: 33-561-491-263


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Insu P. Lee, PhD
Kanazawa University, Japan
Scale Up Production of a Potent Chemopreventive Agent, 1SY16 for Preclinical and Clinical Studies Mushroom Extract (1SY16)

Program Description
Investigators will conduct preclinical development of a Potent Chemopreventive Agent, 1SY16. Preliminary studies have shown that mycochemicals extracted from mushrooms may possess both immunostimulating and antiproliferative properties, and a potent chemopreventive activity in animal models. 1SY16, an extract of Agaricus Blazei Murill, is a mixture of low molecular weight compounds with promising chemopreventive activities. RAPID support will include:

  • Production scale up for 1SY16,
  • In vivo preclinical efficacy studies, preclinical genotoxicity, and
  • Subacute animal toxicity studies.

Contact Information
Insu P. Lee, PhD
Kanazawa University
Japan
Phone: 81-90-372-45628


Back to top

Projects Initiated in FY 2002

Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Thomas M. Badger, PhD
University of Arkansas for Medical Sciences
Shiitake Mushrooms: Do They Prevent Cancer (concluded) Mycochemicals in Shiitake Mushrooms (Lentinus edodes)

Program Description
Investigators will conduct preclinical development of mycochemicals in shiitake mushrooms. Shiitake mushrooms (Lentinus edodes) have been described as having various medicinal properties, including chemopreventive ones. Studies in animal models support anti-cancer activity of Shiitake mycochemicals following oral consumption. RAPID support will include:

  • growth and preparation of standardized log-grown Shiitake mushroom preparation;
  • determination of dietary levels of mushrooms for subsequent studies;
  • development of analytical methods for identification of mushroom mycochemicals;
  • bioactivity based assays to identify mycochemicals;
  • and correlation of mycochemicals in mushrooms, urine, and serum.

Contact Information
Thomas M. Badger, PhD
University of Arkansas for Medical Sciences
Phone: (501) 320-2785
Fax: (501) 320-2818


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Elaine L. Jacobson, PhD
University of Arizona
Development of a Topical Niacin Prodrug for Skin Cancer Prevention Topical Niacin Prodrug

Program Description
Investigators will conduct preclinical development of a topical niacin prodrug for skin cancer prevention. It has been proposed that a topical application of niacin prodrug will prevent, reverse early signs of skin cancers (actinic keratoses), or inhibit progression to cancer. This agent may exert its effects by stimulation of poly(ADP-ribose) polymerase (PARP-1) activity and leptin and their downstream signaling pathways. RAPID support will include:

  • Preclinical toxicology studies,
  • Analytical method development,
  • Absorption/distribution/metabolism/elimination studies, and
  • Animal efficacy studies.

Contact Information
Elaine L. Jacobson, PhD
University of Arizona
College of Pharmacy and Arizona Cancer Center
Tucson, AZ
Phone: (520) 626-2272
Fax: (520) 626-8567


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Andrew J. Gescher, PhD, D.Sc.
University of Leicester, UK
Development of the Brown Rice Constituent Tricin as a Cancer Chemopreventive Agent Flavonoid Tricin

Program Description
Investigators will conduct preclinical development of the brown rice constituent tricin as a cancer chemopreventive agent. The flavonoid tricin has been identified as a constituent of brown rice and rice bran. Preliminary studies have demonstrated biological properties in cells in vitro indicative of chemopreventive activity in vivo. RAPID support will include:

  • synthesis of bulk tricin.

Contact Information
Andrew J. Gescher, PhD, D.Sc.
University Leicester
United Kingdom
Phone: (44) 116 223 1856
Fax: (44) 116 223 1855


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Robert C. Rose, PhD
University of Rochester School of Medicine
Preclinical and Clinical Investigation of the Safety and Tolerability of a Human Papillomavirus (HPV) Virus-Like Particle (VLP) Vaccine Co-administered in Combination with E. Coli Heat-labile Enterotoxin Mutant R192G (LTR192G) by Oral, Intranasal, or Transcutaneous Routes of Immunization (concluded) Human Papillomavirus Virus-like Particle Vaccine

Program Description
Investigators will conduct preclinical and clinical investigation of the safety and tolerability of a human papillomavirus virus-like particle vaccine co-administered in combination with E. coli heat-labile enterotoxin mutant R192G (LTR192G) by oral, intranasal, or transcutaneous routes of immunization. Certain human papillomaviruses cause cervical cancer, which remains a significant source of morbidity and mortality among women worldwide. This project proposes to study the safety and tolerability of a virus-like particle vaccine when co-administered with adjuvant E. coli LTR192G by three alternate routes of delivery (oral, intranasal, or transcutaneous). RAPID support will include production of HPV-16 L1 and E. coli LTR192G for preclinical testing.

Contact Information
Robert C. Rose, PhD
University of Rochester School of Medicine
Rochester, NY
Phone: (716) 275-0263
Fax: (716) 442-9328


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Donald D. Muccio, PhD
University of Alabama
Preclinical Development of 9-cis-UAB30 for Breast Cancer Chemoprevention 9-cis-UAB30 (nuclear retinoid X receptor - RXR)

Program Description
Investigators will conduct preclinical development of 9-cis-UAB30, a nuclear retinoid X selective agonist receptor, for breast cancer chemoprevention. Retinoids that selectively interact with nuclear retinoid X receptors (RXRs) have been shown to be effective in the prevention of mammary cancer either alone or in combination with antiestrogens. 9-cis-UAB30 represents a new class of RXR-selective retinoids and has been shown to be nontoxic and effective in a cancer chemopreventive mammary model. RAPID support will include:

  • bulk synthesis and preclinical toxicology studies.

Contact Information
Donald D. Muccio, PhD
University of Alabama
Birmingham, AL
Phone: (205) 934-4747
Fax: (205) 934-2543


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Leela Srinivas, PhD
Adichunchanagiri Biotechnology and Cancer Research Institute, India
Beta-Turmerin, an Antioxidant from Turmeric (Curcuma longa) Antioxidant from Turmeric (Curcuma longa)

Program Description
Investigators will conduct preclinical development of turmerin, an antioxidant from turmeric (Curcuma longa) waste. Turmerin, a water-soluble peptide represents a novel agent whose biological activity suggests potentially useful chemopreventive activity. Preliminary studies have shown that it is a potent, non-toxic antioxidant, compared to the presently available antioxidant compounds. RAPID support will include bulk supply of turmerin for the proof of concept efficacy testing in standardized models.

Contact Information
Leela Srinivas, PhD
Adichunchanagiri Biotechnology and Cancer Research Institute
India
Phone: 08234-87850
Fax: 08234-87984


Back to top

Projects Initiated in FY 2001

Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Gary H. Posner, PhD
Johns Hopkins University, School of Arts and Sciences
Development of a Novel, Non-calcemic, Hybrid Deltanoid QW-1624F2-2 Synthetic vitamin D analog

Program Description
Synthetic deltanoids (vitamin analogs) exhibit in vivo and in vitro evidence of antiproliferative, proapoptotic, prodifferentiating, and antiangiogenic activities indicative of chemopreventive efficacy. One such analog, QW-1624F2-2 possesses a substantially improved chemopreventive index in terms of its chemopreventive efficacy vs. calcemic toxicity. Preliminary results have shown that it is a potent, effective inhibitor of carcinogenesis in vivo. RAPID support will include synthesis of bulk material for preclinical studies, mutagenicity and short term preclinical toxicity testing, and in vivo screening and efficacy studies.

Contact Information
Gary H. Posner, PhD
Johns Hopkins University School of Arts and Sciences
Department of Chemistry
Baltimore, MD
Phone: (410) 516-4670
Fax: (410) 516-8420


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Robert L. Garcea, MD
University of Colorado School of Medicine
Development of a Next Generation Human Papillomavirus Vaccine Human Papillomavirus Vaccine

Program Description
Investigators will conduct preclinical development of a next generation human papillomavirus vaccine. Human papillomaviruses play a critical role in the development of several cancers, the most common being cervical cancer. A second generation papillomavirus vaccine that is both economical and stable is being developed. Preliminary data showed it offers protection against experimental viral challenge in the canine model. RAPID support will include:

  • In vivo and in vitro preclinical efficacy testing,
  • Preclinical toxicology,
  • GMP production, formulation, and an IND support.

Contact Information
Robert L. Garcea, MD
University of Colorado School of Medicine
Boulder, CO
Phone: (303) 3154-3247
Fax: (303) 315-3244


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
John M. Pezzuto, PhD
Now at the University of Hawaii at Hilo
Preclinical Development of Four Flavonoids from Broussonetia Papyrifera (concluded) Flavonoids

Program Description
Investigators will conduct preclinical development of four flavonoids from Broussonetia papyrifera. Bioassay-guided fractionation of an extract from Broussonetia papyrifera, an endemic edible plant, using an in vitro aromatase inhibition assay led to isolation of four active flavonoid compounds. Preliminary results suggest that these compounds may be effective chemopreventive agents in preventing formation of estrogen-dependent tumors in the breast and the prostate. RAPID support will include:

  • Synthesis of bulk materials for preclinical studies,
  • Mutagenicity and short term preclinical toxicity testing, and
  • In vivo screening and efficacy studies.

Contact Information
John M. Pezzuto, PhD
Dean, College of Pharmacy
University of Hawaii
Phone: (808) 933-2909
Fax: (808) 933-2974


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Fung-Lung Chung, PhD
Presently, Lombardi Comprehensive Cancer Center Georgetown University Medical Center American Health Foundation
Preclinical Development of Sulforaphane, a Major Constituent in Broccoli (concluded) Sulforaphane

Program Description
Investigators will conduct preclinical development of sulforaphane, a major constituent in broccoli. The consumption of cruciferous vegetables is associated with a reduced risk of cancer at various organ sites. Isothiocyanates are abundantly present in these vegetables and are thought to be major contributors to their chemopreventive activities. Sulforaphane is a major isothiocyanate in broccoli and has shown chemopreventive activity in various animal models. RAPID support will include:

  • Synthesis of bulk and 14C-labeled material for preclinical studies,
  • Mutagenicity and short term preclinical toxicity testing,
  • Preclinical absorption, distribution, metabolism, elimination and pharmacokinetic studies,
  • In vivo screening and efficacy studies, and
  • Formulation.

Contact Information
Fung-Lung Chung, PhD
Presently Professor, Department of Oncology
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
3800 Reservoir Rd. NW LL(S) level
Rm 128, Box 571465
Washington, DC 20057-1465
Phone: (202) 687-3021


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Michael B. Sporn, MD
Dartmouth Medical School
Bulk Synthesis of the New Triterpenoids, 2-Carboxy-DDO Methyl Ester and its Homolog, 2-Carboxy-DDO Ethyl Ester (concluded) Triterpenoids

Program Description
Investigators will conduct preclinical development of the new triterpenoids, 2-Carboxy-DDO methyl ester and its homolog, 2-Carboxy-DDO ethyl ester. These 2 new triterpenoids were synthesized to obviate some of the in vivo limitations of their predecessors, namely poor pharmacokinetic profile. Preliminary data suggest that these compounds have numerous activities in cell culture (including inhibition of inducible nitric oxide synthetase and cyclooxygenase-2 and binding to PPAR-g receptor) and in vivo that are relevant to prevention of human cancer. RAPID support will include bulk synthesis of these compounds.

Contact Information
Michael B. Sporn, MD
Dartmouth Medical School
Dartmouth, NH
Phone: (603) 650-6557
Fax: (603) 650-1129


Back to top

Projects Initiated in 2000

Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Peter Collin
Coastside Research
Preclinical development of certain marine derived products, which are proprietary in nature Marine-Derived Products

Program Description
Investigators will conduct preclinical development of certain marine derived products.

Contact Information
Peter Collin
Coastside Research
Stonington, ME
Phone: (207) 367-2297
Fax: (207) 367-5929


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Clement Ip, PhD
Roswell Park Cancer Institute
Evaluation of Se-methylselenocysteine for cancer prevention Selenium Containing Amino Acid

Program Description
Investigators will evaluate Se-Methylselenocysteine, a selenium containing amino acid. The substance is a good precursor of methylselenol and this monomethylated selenium is an important factor in chemoprevention. Se-Methylselenocysteine is found in many plant species, e.g. garlic, broccoli, and onions. It has been shown to inhibit the growth of chemically induced tumors in animal models at dietary concentrations as low as 2 ppm selenium. RAPID support will include:

  • Mutagenicity and short-term preclinical toxicity testing,
  • GMP synthesis, formulation, and packaging, and IND support.

Contact Information
Clement Ip, PhD
Roswell Park Cancer Institute
New York, NY
Phone: (716) 845-8875
Fax: (716) 845-8100


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Arthur G. Schwartz, PhD
Temple University of School of Medicine, Fels Institute for Cancer Research and Molecular Biology
Development of DHEA-analog, Fluasterone, for efficacy trials in cancer prevention Fluasterone

Program Description
Investigators will conduct preclinical development of DHEA-analog, Fluasterone, for efficacy trials in cancer prevention. The already developed synthetic steroid, fluasterone (16a-fluoro-5-androsten-17-one), which like its naturally occurring counterpart, adrenocortical steroid DHEA (dehydroepiandrosterone) exhibits chemopreventive activity in laboratory rodent models. However, fluasterone unlike DHEA lacks sex hormonal and liver perixosome proliferating effects. RAPID support will include studies:

  • Chronic preclinical toxicology studies in dog and rat,
  • Synthesis of C-14 fluasterone,
  • Preclinical absorption, distribution, metabolism, elimination and pharmacokinetic.

Contact Information
Arthur G. Schwartz, PhD
Temple University School of Medicine,
Fels Institute for Cancer Research and Molecular Biology
Pennsylvania
Phone: (215) 707-4349
Fax: (215) 707-7473


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Thomas W. Kensler, PhD
Johns Hopkins University, Bloomberg School of Hygiene and Public Health
Preclinical development of a new generation dithiolethione (concluded) 5,6-dihydro-4H-cyclopenta-1,2 dithiole-3-thione

Program Description
Investigators will conduct preclinical development of 5,6-dihydro-4H-cyclopenta-1,2-dithiole-3-thione, a Selective Phase II Enzyme inducer for cancer prevention. Induction of phase II enzymes, which neutralize reactive electrophiles and act as indirect antioxidants, is an effective means for achieving protection against a variety of carcinogens in animals an humans. A new generation of selective phase II inducers, dithiolethiones with greater efficacy and potency than oltipraz, was developed. One of these, 5,6-dihydro-4H-cyclopenta-1,2-dithiole-3-thione appears to have desirable safety and efficacy profile and an easy and inexpensive synthesis. RAPID support will include:

  • Synthesis of bulk material for preclinical studies,
  • Mutagenicity and short term preclinical toxicity testing,
  • And in vivo screening and efficacy studies.

Contact Information
Thomas W. Kensler, PhD
Johns Hopkins University
Bloomberg School of Hygiene and Public Health
Baltimore, MD
Phone: (410) 955-4712
Fax: (410) 955-0116


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
John M. Pezzuto, PhD
Now at the University of Hawaii at Hilo
Evaluation of 4'-Bromoflavone for cancer prevention (concluded) 4'-Bromoflavone

Program Description
Investigators will evaluate 4'-Bromoflavone for cancer prevention. Induction of phase II detoxifying enzymes is an important mechanism of chemoprevention. 4'-Bromoflavone was shown to induce glutathione S-transferase and quinone reductase. It has been also shown to inhibit carcinogen covalent binding to cellular DNA and to inhibit incidence and multiplicity and increase tumor latency in carcinogen animal models. RAPID support will include:

  • Synthesis of bulk material for preclinical studies,
  • Mutagenicity and short term preclinical toxicity testing,
  • And in vivo screening and efficacy studies.

Contact Information
John M. Pezzuto, PhD
Dean, College of Pharmacy
University of Hawaii
Phone: (808) 933-2909
Fax: (808) 933-2974


Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Harold L. Newmark, DSci
Rutgers, The State of University of New Jersey
Evaluation of farnesol and geraniol in human pancreatic cancer (concluded) Farnesol and Geraniol

Program Description
Investigators will conduct clinical testing of farnesol and geraniol in human pancreative cancer. Pancreatic cancer is rapidly growing and highly lethal. An average survival is less than 12 months and present chemotherapy extends survival by only few months. Farnesol and geraniol are found at low levels in several foods and essential oils and have been found to be potent inhibitors of human pancreatic tumor cell growth in vitro and pancreatic tumor growth in hamsters in vivo. RAPID support will include:

  • Mutagenicity and short term preclinical toxicity testing,
  • In vivo screening and efficacy testing,
  • GMP synthesis, formulation, packaging, IND support, and
  • Phase I studies.

Contact Information
Harold Newmark, DSci
Rutgers, The State University of New Jersey
New Jersey
Phone: (732) 445-3400, ext. 242
Fax: (732) 445-0687


^
Principal Investigator
& Institute
Title of Project Prevention Agent
Under Study
Eytan R. Barnea, MD
The Society of the Investigation of Early Pregnancy
Preclinical development of developmental peptides (DPs) as biopreventive agents (concluded)Developmental Peptides

Program Description
Investigators will conduct preclinical development of Developmental Peptides as biopreventive agents. Both embryogenesis and cancer are associated with rapid cell proliferation. Unlike cancer, embryogenesis is characterized by a delicate balance of proliferative and anti-proliferative processes. In preliminary studies, several peptide fractions from mammalian embryonic tissues have shown antiproliferative activity in cancer cells in cultures. RAPID support will include:

  • In vitro bioassay guided isolation,
  • Purification, and characterization of active fractions, and
  • In vitro and in vivo assay of more active fractions in rodent biopreventive tests.

Contact Information
Eytan Barnea, MD
The Society for the Investigation of Early Pregnancy
New Jersey
Phone: (856) 429-2699
Fax: (856) 429-7414


Back to top